Toll-like receptor 9 and Toll-like receptor 2 (TLR9/TLR2)

Toll-like receptor 9 (TLR9) and Toll-like receptor 2 (TLR2) are critical pattern recognition receptors (PRRs) that play a fundamental role in the innate immune system by detecting pathogen-associated molecular patterns (PAMPs). TLR2 is a cell-surface receptor that recognizes a variety of microbial components, including lipoproteins and peptidoglycans from bacteria, while TLR9 is an endosomal receptor that specifically detects unmethylated CpG DNA motifs common in bacterial and viral genomes [1, 2]. Upon activation, both receptors signal through the MyD88 adapter protein, initiating a cascade that activates NF-kappaB and Interferon Regulatory Factors (IRFs), leading to the production of pro-inflammatory cytokines and type I interferons [3]. This signaling bridge connects innate recognition to the recruitment and activation of adaptive immune cells, such as dendritic cells and T-lymphocytes. In clinical development, these receptors are targeted primarily in oncology to enhance the immunogenicity of the tumor microenvironment, often using synthetic agonists like lefitolimod or vidutolimod to stimulate anti-tumor T-cell responses [5]. The mention of "broader immune cell pathways" typically refers to this downstream signaling axis (MyD88/NF-kappaB) which is shared by multiple TLRs and is a focal point for therapeutic modulation in inflammatory and infectious diseases.

Other names

TLR9TLR2CD282CD289Toll-like receptor 9Toll-like receptor 2

Agonism of TLR2 and TLR9 triggers the MyD88-dependent signaling pathway, leading to the activation of NF-kappaB and IRF7, which induces the expression of pro-inflammatory cytokines and type I interferons to stimulate innate and adaptive immunity [3, 4].